Ozempic and Wegovy are two of the most-searched injection pens in Ireland, and the names get used almost interchangeably on social media. They are closely related products from the same company, but they are not the same medicine in practice: they are licensed for different conditions, and they come in different doses. Here is what the official European product information actually says about each, in plain English.
Ozempic vs Wegovy in Ireland: the quick answer
Quick answer (checked 7 October 2026): Ozempic and Wegovy both contain the same active ingredient, semaglutide, made by Novo Nordisk and injected once a week. The difference is the licence. Ozempic is authorised for adults with insufficiently controlled type 2 diabetes. Wegovy is authorised for weight management in adults with a BMI of 30 or above, or 27 to under 30 with a weight-related condition. Ozempic is not licensed for weight loss anywhere in the EU.
Try the Slimbr weight loss plan
First month service fee just €49. If the doctor decides it's not suitable for you, your doctor consultation is free.
The same active ingredient: semaglutide
Semaglutide belongs to the group of medicines called GLP-1 receptor agonists. GLP-1 is a naturally occurring hormone involved in regulating appetite and blood sugar. Semaglutide acts like this hormone: it slows how quickly the stomach empties, increases feelings of fullness after eating, and helps the body release insulin when blood sugar rises.
Because Ozempic and Wegovy share the same active ingredient, much of their product information looks similar: the injection technique (a small needle under the skin of the stomach, thigh or upper arm), the weekly schedule, the common stomach and bowel side effects, and many of the precautions. The differences that matter are about who each product is licensed for and what doses it comes in.
The main difference: what each is licensed for
A medicine's licence is the formal statement, approved by the European Medicines Agency (EMA), of the condition it may be used to treat. This is not a technicality. It defines which patients the medicine was studied in, what the patient leaflet says, and what a prescriber is working from. The two licences are:
- Ozempic: "Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise" (EMA product information, section 4.1). Ozempic has been authorised in the EU since February 2018. Weight management does not appear in its licence.
- Wegovy: weight management, alongside a reduced-calorie diet and increased physical activity, in adults with a BMI of 30 or above (obesity), or 27 to under 30 (overweight) with at least one weight-related condition. It is also licensed for adolescents aged 12 and over with obesity and a body weight above 60 kg. Wegovy has been authorised in the EU since January 2022 and became available in Irish pharmacies in 2025.
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Licensed for | Type 2 diabetes | Weight management |
| How often | Once a week | Once a week |
| Pen strengths | 0.25, 0.5, 1 and 2 mg | Escalating to 2.4 mg (7.2 mg option for some adults) |
| Also available as | — | A daily tablet (oral semaglutide) |
| First authorised in EU | February 2018 | January 2022 |
Why everyone talks about Ozempic for weight loss anyway
Search "Ozempic" and most of what you find is about weight. The name became shorthand for injectable weight-loss medicine through social media and celebrity coverage from around 2022 onwards, when demand for the diabetes pen rose sharply. So it is worth being precise about what is and is not true.
What is true: semaglutide, the ingredient in Ozempic, is licensed for weight management in the higher-dose Wegovy pens. What is not true: that Ozempic itself is a licensed weight-loss medicine. A doctor can make a prescribing decision outside a product's licence when they judge it clinically appropriate for a specific patient — that is a medical decision made case by case, with the patient informed. It is not something an article, an influencer or an advertisement can decide.
The licence criteria also answer a question that circulates widely on social media — "can I get Ozempic to slim down before a wedding?" The honest answer is that licensed weight-management treatment is for people whose weight meets the medical definition of obesity (or overweight with a weight-related condition), not for people at a normal body weight who want to be thinner for an event. A reputable prescriber works to those criteria, and a genuine assessment can end in "no".
Who Wegovy is licensed for
The EMA product information for Wegovy (section 4.1) covers, alongside a reduced-calorie diet and increased physical activity:
- Adults with a starting BMI of 30 or above (obesity), or 27 to under 30 (overweight) with at least one weight-related condition. The conditions listed are: prediabetes or type 2 diabetes, high blood pressure, abnormal blood fats (dyslipidaemia), obstructive sleep apnoea, or cardiovascular disease.
- Adolescents aged 12 and over with obesity (by international BMI cut-offs for young people) and a body weight above 60 kg.
BMI is a starting filter, not a verdict. Meeting the BMI threshold does not mean a medicine is suitable; other health factors, other medicines and personal history all matter, and the decision sits with a prescriber. People who do not meet the thresholds are not candidates for licensed treatment, however persuasive the before-and-after photos.
How the doses differ
Both pens start low and build up over weeks, because the slow escalation improves stomach tolerability. But the schedules and strengths are different products of their different licences:
- Ozempic starts at 0.25 mg once weekly for at least four weeks, moves to 0.5 mg once weekly, and can then be increased to 1 mg after at least four weeks, or to 2 mg once weekly after at least four weeks on 1 mg — as treatment for type 2 diabetes.
- Wegovy starts at 0.25 mg once weekly and escalates step by step to the standard maintenance dose of 2.4 mg once weekly. The product information also includes a 7.2 mg once-weekly option for adults whose starting BMI was 30 or above, added only after at least four weeks on the 2.4 mg dose, and says the dose should go back to 2.4 mg if there is no additional benefit.
Wegovy's product information covers a missed dose within 5 days: take it as soon as possible and continue the usual schedule. Beyond 5 days, skip the missed dose. Dose changes are made by the prescriber, not by the patient — this is a summary of the product information, not dosing instructions for your own pen.
Wegovy also comes as a tablet
There is now an oral form: a once-daily Wegovy tablet containing semaglutide 25 mg. The product information says people taking the tablet can be transitioned to the 2.4 mg weekly injection. A tablet rather than an injection matters to many people with needle anxiety or busy routines. We cover the tablet version, and how it differs from the injection, in our full article on the Wegovy tablet in Ireland.
Did you know you can claim up to 75% back on your health insurance?
See how the claim works →Do Ozempic and Wegovy have the same side effects?
Largely, because the active ingredient is the same. In both products' information the "very common" side effects (meaning more than 1 in 10 people) are the stomach and bowel ones — nausea, vomiting, diarrhoea, constipation — along with headache for Wegovy. Nausea is the most talked-about, typically worst in the first weeks of a dose increase, and the slow dose escalation exists precisely to reduce it.
Both products also carry the same class warnings: inflammation of the pancreas, gallstones, dehydration from persistent vomiting, and a caution about thyroid in the product information. None of this is a reason to avoid assessment; it is a reason to be supervised while taking it, so symptoms are caught and dosing adjusted. The full frequency lists are in our semaglutide side effects article.
One concern people raise alongside any fast weight loss is muscle. Losing weight quickly without enough protein or resistance exercise can reduce lean mass as well as fat. That is not a reason to avoid treatment; it is a reason to keep protein and strength work part of the plan — see our guide to preserving muscle on GLP-1 medicines.
Try the Slimbr weight loss plan: first month service fee just €49 →
What Ozempic and Wegovy cost in Ireland
Both are prescription-only medicines; for weight management they are currently only available privately, and prices are set by pharmacy and supplier and change over time — we deliberately do not quote figures here, because a stale price is worse than none. We keep current Irish pricing, and how the cost compares across products, in our Ozempic cost in Ireland guide, which also covers what affects the price month to month.
The practical point for anyone budgeting: licensed treatment is open-ended, not a one-off purchase. It starts with an assessment, continues with regular check-ins, and the ongoing cost follows however long treatment lasts for you. Any service that quotes a price before a medical assessment has the order of operations wrong.
Does the HSE cover Ozempic or Wegovy?
As of the most recent public position (February 2026), neither Ozempic nor Wegovy is reimbursed for weight management on the community drug schemes. In a written reply to Dáil éireann, the HSE confirmed that applications for Wegovy (and for Mounjaro for weight management) were still under consideration as of that reply. Type 2 diabetes use of Ozempic follows the general rules for diabetes medicines on the schemes.
One weight-management injection is reimbursed, in a narrow group: Saxenda, under a HSE managed access protocol in place since January 2023, for adults with a BMI of 35 or above who also have prediabetes and high cardiovascular risk, approved patient by patient on application by the prescriber. Reimbursement criteria change, so confirm the current position with your GP or the HSE.
So which one is right for you?
That is the wrong question to answer from an article, and any page that answers it without a medical assessment is guessing. The brand is the last step, not the first. What actually decides treatment is the medical picture: BMI and history, other conditions, other medicines, previous attempts, and what the prescriber judges appropriate — which may be a different medicine entirely, or none.
Wegovy and Mounjaro are the weight-management treatments doctors can assess through Slimbr. The assessment reviews the whole picture, and a genuine review can conclude that prescription treatment is not appropriate.
If you would rather have a doctor look at the whole picture than compare brand names, the starting point is a proper medical assessment.
See if the Slimbr plan is right for you: first month service fee just €49 →
Frequently asked questions
Is Ozempic the same as Wegovy?
They contain the same active ingredient, semaglutide, and are made by the same company. They differ in their licence (Ozempic for type 2 diabetes, Wegovy for weight management), their pen strengths and their maximum doses.
Can you get Ozempic for weight loss in Ireland?
Ozempic is not licensed for weight loss; its EU licence covers type 2 diabetes. The semaglutide product licensed for weight management is Wegovy. Whether any medicine is appropriate for an individual is a decision for a prescriber.
Which is stronger, Ozempic or Wegovy?
The question does not have a meaningful answer, because the two products are dosed for different purposes. Ozempic's type 2 diabetes doses go up to 2 mg weekly; Wegovy's weight-management maintenance dose is 2.4 mg weekly, with a 7.2 mg option for some adults. They are not interchangeable, and there is no approved way to convert between them.
Do Ozempic and Wegovy have the same side effects?
Very similar, because the active ingredient is the same. Very common effects are the stomach and bowel ones — nausea, vomiting, diarrhoea, constipation — and usually strongest in the first weeks of a dose increase.
Is Wegovy available in Irish pharmacies?
Yes. Wegovy was authorised EU-wide in January 2022 and became available in Ireland in 2025. It is prescription-only and dispensed through pharmacies.
Does a medical card or the Drugs Payment Scheme cover them?
As of February 2026, neither is reimbursed for weight management on the community drug schemes; the HSE confirmed Wegovy's application was still under consideration. Saxenda is the one weight-management injection reimbursed, in a narrow group under a managed access protocol.
Can you switch from Ozempic to Wegovy?
Any switch between products is a prescribing decision, taking into account your history, current dose and treatment goal. Do not plan a switch yourself; raise it with the clinician supervising your treatment.
Further reading
- Ozempic cost in Ireland — current pricing and what affects it
- The Wegovy tablet in Ireland — oral semaglutide vs the injection
- Semaglutide side effects — the full frequency lists
- Every weight-loss medication licensed in Ireland — injections and tablets compared
- Mounjaro in Ireland: the complete guide — how the treatment works and follow-up
Sources: European Medicines Agency product information (SmPC) for Ozempic and Wegovy (sections 4.1 and 4.2), read in full 7 October 2026. HSE Primary Care Reimbursement Service reply to PQ 10654/26 (17 February 2026). HSE managed access protocol for liraglutide (Saxenda), version 1.2. This article is general information, not medical advice; ask a doctor or pharmacist about your own situation.
